It's a targeted world in non-Hodgkin's lymphoma

Okosun, Jessica; Fitzgibbon, Jude
September 2011
British Journal of Nursing;9/22/2011 Supplement, pS28
Academic Journal
In this article the authors discuss targeted therapies which are used in the treatment of non-Hodgkin's lymphoma. They are supportive of the use of targeted therapies in cancer patients and of research which is being conducted and may be conducted in the future on tumors and which may lead to innovative options in cancer treatment.


Related Articles

  • O1–069INFLUENCE OF RITUXIMAB PLUS BENDAMUSTINE CHEMOTHERAPY ON THE IMMUNE SYSTEM IN LYMPHOMA PATIENTS. Ito, K.; Okamoto, M.; Ando, Y.; Ando, M.; Kumazawa, S.; Okamoto, A.; Inaguma, Y.; Ohta, H.; Yamada, S.; Emi, N. // Annals of Oncology;Nov2013 Supplement 9, Vol. 24, pix37 

    No abstract available.

  • Will rituximab replace watchful waiting as the most attractive strategy for treating asymptomatic follicular lymphoma patients? Cabanillas, Fernando; Conners, Joseph M. // Hem/Onc Today;2/10/2011, Vol. 12 Issue 3, p11 

    The article presents views on rituximab replacement of watchful waiting as the most attractive strategy for treating asymptomatic follicular lymphoma patients.

  • Antineoplastics: Various toxicities: case report.  // Reactions Weekly;Dec2013, Issue 1481, p7 

    The article presents a case study of a 44-year-old woman who experienced several toxicities while receiving chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone for plasmablastic lymphoma.

  • Review of the Safety and Feasibility of Rapid Infusion of Rituximab. Atmar, Jill // Journal of Oncology Practice;Mar2010, Vol. 6 Issue 2, p91 

    The article examines the safety and feasibility of rapid infusion of rituximab in the treatment of cancer. It notes that it is a chimeric monoclonal antibody that targets the B-cell CD20 antigen and causes rapid and specific B-cell depletion in which when added to standard chemotherapy regimens...

  • hematological malignancies.  // Annals of Oncology;Sep2008 Supplement 8, Vol. 19, p229 

    The article presents abstracts on hematological malignancies which include treatment of patients with relapsed, refractory mantle cell lymphoma with temsirolimus, in vitro effects of eltrombopag on proliferation and differentiation of leukemia cell lines, and the use of rituximab and...

  • Primary gastric Burkitt's lymphoma. Mitra, Swarupa; Mehta, Anurag; Gupta, Sunil Kumar; Sharma, Anila; Louis, A. Robert; Sharma, Manoj Kumar; Saxena, Upasna; Simson, David K.; Dewan, Abhinav // Rare Tumors;2014, Vol. 6 Issue 4, p128 

    The primary gastrointestinal non-Hodgkin's lymphoma, although rare, is among the most common extra-nodal lymphomas, considering that gastric lymphomas are more common than intestinal lymphomas. Burkitt's lymphoma (BL) is an aggressive form of B-cell lymphoma that is typically endemic in Africa,...

  • GlycoGenesys' GCS-100 induces cell death in lymphoma.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p23 

    Reports that GlycoGenesis presented positive clinical data demonstrating that the investigational compound GCS-100 killed both a chemotherapy-resistant human lymphoma cell line that over expressed the Bcl-2 protein and an identical non-Bcl-2-over-expressing human lymphoma cell line in vitro. ...

  • Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. Pellegrini, Cinzia; Stefoni, Vittorio; Casadei, Beatrice; Maglie, Roberto; Argnani, Lisa; Zinzani, Pier // Annals of Hematology;Nov2014, Vol. 93 Issue 11, p1853 

    The choice of treatment for cutaneous T cell lymphoma (CTCL) is often determined by institutional experience, particularly as there is a paucity of data from phase III trials and a lack of consensus concerning treatment of the advanced stages. Among the several second-line and experimental...

  • Bendamustine and Rituximab (BR) Regimen for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Lee, Jessica N.; Waddell, J. Aubrey; Solimando, Jr, Dominic A. // Hospital Pharmacy;Oct2012, Vol. 47 Issue 10, p762 

    The article focuses on bendamustine and rituximab (BR) Regimen against indolent and mantle cell lymphomas, aggressive B-cell lymphomas and refractory chronic lymphocytic leukemia (CLL). It explains how bendamustine and rituxiamb injections are prepared. Bendamustine preparation is administered...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics